STOCK TITAN

Aadi Bioscience, Inc. - AADI STOCK NEWS

Welcome to our dedicated page for Aadi Bioscience news (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.

Aadi Bioscience, Inc. (NASDAQ: AADI) is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway. The company's lead asset, FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension), is an mTOR inhibitor targeting cancers driven by genetic alterations in mTOR pathway genes. Aadi is committed to bringing transformational therapies to cancer patients with mTOR pathway driver alterations such as those in the TSC1 or TSC2 genes.

Aadi Bioscience has received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO® is designed to improve delivery, stability, solubility, and targeting compared to traditional mTOR inhibitors and is being evaluated in various clinical trials. The company's innovative approach combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus.

The company's clinical pipeline includes the Phase 2 PRECISION1 trial, a tumor-agnostic registration-intended study exploring nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The trial is expected to complete enrollment by the end of 2024, with interim analysis anticipated in Q3 2024.

In addition to PRECISION1, Aadi is conducting two other Phase 2 trials: one in advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole, and another in neuroendocrine tumors (NETs). Endometrial cancer is a common type of gynecologic cancer, and nab-sirolimus has shown promise in combination therapies for these difficult-to-treat cancers.

Financially, Aadi's Q1 2024 revenue from FYARRO® sales reached $5.4 million, reflecting a strong market presence as the preferred treatment for malignant PEComa. The company's robust financial position, with $88.3 million in cash and short-term investments as of March 2024, is expected to fund operations into Q4 2025.

Headquartered in Los Angeles, Aadi Bioscience is led by a team of industry veterans with extensive experience in developing and commercializing blockbuster oncology products. The company's mission is to unlock the full potential of mTOR inhibition and bring hope to patients with genetically-defined cancers.

Rhea-AI Summary
Aadi Bioscience, Inc. will host a conference call and webcast on November 8, 2023, to report third quarter 2023 financial results and provide an operational update. Participants can access the live webcast on the company's website and register in advance to participate via telephone. A replay of the conference call and webcast will be available on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
conferences earnings
-
Rhea-AI Summary
Aadi Bioscience initiates Phase 2 trial for the treatment of endometrial cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience announces details of four poster presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
Rhea-AI Summary
Aadi Bioscience to present two posters at the North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience grants equity award to new CEO, Dave Lennon, with a nonstatutory stock option to purchase 490,000 shares of common stock at an exercise price of $4.30 per share. The option will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
management
-
Rhea-AI Summary
Aadi Bioscience appoints Dr. Dave Lennon as President and CEO, bringing over 20 years of pharmaceutical experience and expertise in mTOR inhibitors. Leadership transition expected to accelerate growth and leverage nanoparticle technology in FYARRO. On track for interim analysis on 40 patients in PRECISION1 trial and trial initiations in endometrial and neuroendocrine cancers. Dr. Lennon's appointment expected to accelerate Aadi's growth as a precision oncology company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.16%
Tags
management
Rhea-AI Summary
Aadi Bioscience announces four abstracts selected for presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) announces participation in investor events: H.C. Wainwright 25th Annual Global Investment Conference and Morgan Stanley 21st Annual Global Healthcare Conference. CEO and CFO will present and participate in fireside chat respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
conferences
-
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) reports a 6% increase in FYARRO sales to $6.2 million in 2Q 2023, with plans for an interim analysis on 40 patients in the PRECISION1 trial before the end of 2023. The company is expanding its pipeline to include programs in Endometrial Cancer and Neuroendocrine Tumors (NETs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences earnings

FAQ

What is the current stock price of Aadi Bioscience (AADI)?

The current stock price of Aadi Bioscience (AADI) is $1.96 as of November 4, 2024.

What is the market cap of Aadi Bioscience (AADI)?

The market cap of Aadi Bioscience (AADI) is approximately 49.0M.

What is Aadi Bioscience, Inc.?

Aadi Bioscience, Inc. is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway.

What is FYARRO®?

FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension) is an mTOR inhibitor developed by Aadi Bioscience for treating cancers driven by genetic alterations in mTOR pathway genes.

What are the key clinical trials of Aadi Bioscience?

Aadi Bioscience's key clinical trials include the Phase 2 PRECISION1 trial for solid tumors with TSC1 or TSC2 inactivating alterations, a Phase 2 trial in advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole, and a Phase 2 trial in neuroendocrine tumors (NETs).

What financial results did Aadi Bioscience achieve in Q1 2024?

In Q1 2024, Aadi Bioscience achieved $5.4 million in revenue from FYARRO® sales. The company had $88.3 million in cash and short-term investments as of March 2024.

What is the significance of the mTOR pathway in cancer treatment?

The mTOR pathway is a key regulator of cell growth and cancer progression. Alterations in this pathway can lead to various cancers. Aadi Bioscience focuses on developing therapies targeting these alterations to treat genetically-defined cancers.

Where is Aadi Bioscience headquartered?

Aadi Bioscience is headquartered in Los Angeles, California.

Who leads Aadi Bioscience?

Aadi Bioscience is led by a team of industry veterans with extensive experience in developing and commercializing blockbuster oncology products.

What are the upcoming milestones for Aadi Bioscience?

Upcoming milestones for Aadi Bioscience include the two-thirds interim analysis of the PRECISION1 trial in Q3 2024, full enrollment in the trial by the end of 2024, and ongoing enrollment in Phase 2 trials for EEC and NETs.

What are the potential benefits of nab-sirolimus?

Nab-sirolimus combines nanoparticle albumin-bound technology with sirolimus to improve drug delivery, stability, solubility, and targeting, potentially overcoming limitations of traditional mTOR inhibitors.

What is the mission of Aadi Bioscience?

Aadi Bioscience's mission is to unlock the full potential of mTOR inhibition and bring transformational therapies to cancer patients with genetically-defined cancers.

Aadi Bioscience, Inc.

Nasdaq:AADI

AADI Rankings

AADI Stock Data

48.98M
24.62M
9.97%
60.17%
1.15%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PACIFIC PALISADES